DT
PT
Subscribe To Print Edition About The Tribune Code Of Ethics Download App Advertise with us Classifieds
search-icon-img
search-icon-img
Advertisement

Claims about PresVu eye drop false, unethical: DCGI

Explanation sought from pharma firm
  • fb
  • twitter
  • whatsapp
  • whatsapp
featured-img featured-img
Photo for representational purpose only.
Advertisement

The claims made by ENTOD Pharmaceuticals that its product PresVu eye drops had been approved by Drug Controller General of India (DCGI) and that the drug offered spectacular treatment for presbyopia were unethical and false presentation of facts, a top official source said. A DGCI official said an explanation had been sought from the company.

“This is unethical and false presentation of facts. Explanation has been sought from the company,” a top source said.

ENTOD Pharmaceuticals had said: “PresVu is the first eye drop in India specifically developed to reduce dependency on reading glasses for individuals affected by presbyopia, a common age-related vision condition that typically impacts those over 40.”

Advertisement

Company CEO Nikkhil K Masurkar had claimed that PresVu was the result of years of dedicated research and development and it had secured DCGI’s approval.

Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
tlbr_img1 Home tlbr_img2 Opinion tlbr_img3 Classifieds tlbr_img4 Videos tlbr_img5 E-Paper